{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/gastroenteritis/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"f4287eb4-029e-5263-ae00-6b8ece9aff32","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 77d846b9-2e52-434d-8c87-c89955655c28 --><h2>Changes</h2><!-- end field 77d846b9-2e52-434d-8c87-c89955655c28 -->","summary":null,"htmlStringContent":"<!-- begin item 18a0e258-cf3e-4e51-8f1d-5d094ffca1ad --><!-- begin field 3cabe7fe-5c68-451f-b9b1-0a81489d3ce3 --><p><strong>July to August 2020 </strong>— reviewed. A literature search was conducted in July 2020 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. The topic has undergone major restructuring, with several nodes merged to improve clarity and navigation. The node on Prevalence has been deleted and the content incorporated into the Causes section. The Scenario: Child - remote presentation has been deleted, and the content incorporated into the Scenario: Child. The sections on diagnosis and management have been updated in line with Public Health England (PHE) and other current literature. The Prescribing information section has been updated with currently recommended drugs to prescribe in primary care for acute gastroenteritis owing to specific causes.</p><!-- end field 3cabe7fe-5c68-451f-b9b1-0a81489d3ce3 --><!-- end item 18a0e258-cf3e-4e51-8f1d-5d094ffca1ad -->","topic":{"id":"b4861e4a-0cf5-5fed-b83a-a57e60b78a80","topicId":"f3241704-6943-4c6f-9689-cf06812d0832","topicName":"Gastroenteritis","slug":"gastroenteritis","lastRevised":"Last revised in August 2020","chapters":[{"id":"6d884ff2-d64b-55ab-aae4-78f940a95f30","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"2b8c6f38-638e-5804-8318-e1b14304e522","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"94101b20-12cb-5041-a413-6dcc12af895e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f4287eb4-029e-5263-ae00-6b8ece9aff32","slug":"changes","fullItemName":"Changes"},{"id":"4d578aaa-9662-5914-903d-e36514be32a0","slug":"update","fullItemName":"Update"}]},{"id":"d01dac38-120c-51d7-a620-b85d40b1eb15","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"cd1552a6-5a2d-563b-a242-29bd94992517","slug":"goals","fullItemName":"Goals"},{"id":"b7b0c03c-8588-5565-82d9-9cfe2d111d41","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b32a632a-610d-59de-bf5f-d79f466a66b7","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"28e54d5a-177d-5e18-9753-67134efb41a6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"2b2f62eb-7996-5b9c-88ed-3648b2e3721d","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"1e2a0d5e-dba9-54fe-99e1-1e33dd814faa","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d382f491-ad27-5dbc-bfa7-806501a73eb5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"c6b1334e-cda3-5363-a887-f24bcde0b626","slug":"definition","fullItemName":"Definition"},{"id":"501c659b-1656-5ad1-b381-f3042ed81bec","slug":"causes","fullItemName":"Causes"},{"id":"2e6d28a0-305f-5c3c-983a-62e1631c41b8","slug":"complications","fullItemName":"Complications"}]},{"id":"71e06d5f-9179-5a88-986f-34fd82eab600","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"de24a8b0-cda2-5be8-8fbf-df6ddf6fb6eb","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"3f17076e-616a-532c-a5ee-d6a5d2104dc5","slug":"assessment","fullItemName":"Assessment"},{"id":"bf8cbeb8-b0a5-5ebc-9cfc-7ba3beb62c6b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"34db7d00-7fa0-5e11-a2b2-0e045c80e236","fullItemName":"Management","slug":"management","subChapters":[{"id":"64ea9cd1-ae9b-5d77-bc7b-1df0c42b3d66","slug":"child-gastroenteritis","fullItemName":"Scenario: Child gastroenteritis"},{"id":"97ae699a-60c4-5649-a4ad-f0bbdf5c7aa5","slug":"adult-gastroenteritis","fullItemName":"Scenario: Adult gastroenteritis"}]},{"id":"3874a053-755a-5518-961d-b6811d36d278","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a6969159-fdcf-5f1f-ac9a-c8bcf291abdc","slug":"tinidazole","fullItemName":"Tinidazole"},{"id":"ddc9423c-8dd0-5c5b-b208-f261c2cd777d","slug":"clarithromycin","fullItemName":"Clarithromycin"}]},{"id":"84f507dc-726d-559a-b788-9c91297b0fd0","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2e6aa3b5-4c48-538f-bc1e-8c97a0e4940e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"60c6fc26-4bfa-5e0d-bba6-0ebffc61d83b","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0cb4826a-19bb-549f-b65f-2f5ad75883bc","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b05f7822-56ab-538c-9fb0-fd20a99810a2","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"8bc3886a-0fd7-52a0-9be2-506de8584bc9","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"a0898f71-226b-5af6-87b5-20b9c6c1fe78","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a52fa5fd-99e9-5dd5-b626-0e429b2424e3","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"94101b20-12cb-5041-a413-6dcc12af895e","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"fa8df62c-5a6a-5b4d-bed7-b4f24c7c357d","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 233efcdc-276d-4f77-8797-cbbe7588e2c0 --><h3>Previous changes</h3><!-- end field 233efcdc-276d-4f77-8797-cbbe7588e2c0 -->","summary":null,"htmlStringContent":"<!-- begin item e86e4f94-3332-4e5f-bfed-48e4d4102c20 --><!-- begin field c1375ac8-11d6-4583-aeb5-85f95078e0c0 --><p><strong>March 2019 </strong>— minor update. Prescribing information for quinolones has been updated in line with the Medicines and Healthcare products Regulatory Agency (MHRA) publication <em>Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects </em>(2019).</p><p><strong>January 2019</strong> — minor update. Aortic aneurysm and dissection is now listed as an adverse effect of ciprofloxacin in the section on Prescribing information. </p><p><strong>October 2018 </strong>— minor update. Adverse effects of metronidazole updated in the Prescribing information section.</p><p><strong>September 2017 </strong>— minor update. Text update on quinolones according to the manufacturers' Summary of Product Characteristics (SPC), to align all CKS topics advice on prescribing. </p><p><strong>November 2016 </strong>— minor update. The adverse effects of loperamide have been updated to include information in a US Food and Drug Administration (FDA) 2016 drug safety communication, warning that exceeding the maximum dose can cause serious cardiac problems including QT interval prolongation, Torsades de Pointes or other ventricular arrhythmias, syncope, and cardiac arrest.</p><p><strong>July 2015 </strong>—<strong> </strong>minor update. Information on the concurrent use of clarithromycin or erythromycin with statins has been clarified.</p><p><strong>August 2014 </strong>—<strong> </strong>reviewed. A literature search was conducted in July 2014 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of the topic. No major changes to clinical recommendations have been made. However, some sections have been reworded for clarity, and overview sections have been added in each scenario.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>August 2011 </strong>— minor update. Text changed to include advice on the management of acute bloody diarrhoea potentially caused by vero cytotoxin-producing <em>Escherichia coli </em>in children. Several minor typographical errors corrected. Issued in September 2011.</p><p><strong>May 2011 </strong>— minor update. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>March 2011 </strong>— topic structure revised to ensure consistency across CKS topics. No changes to clinical recommendations have been made.</p><p><strong>August 2010 </strong>— minor update. Following a recent outbreak of <em>Escherichia coli </em>0157 at an open farm in the UK, the Health Protection Agency (HPA) has reminded prescribers that children with bloody diarrhoea should be admitted to hospital, to confirm the diagnosis and prevent the spread of infection to others in the household. Issued in August 2010.</p><p><strong>April 2010 </strong>— minor update. New notifiable diseases advice has been issued by the Department of Health. Issued in April 2010.</p><p><strong>July to September 2009 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. The information on prevention of travellers' diarrhoea and management of a person with <em>Clostridium difficile </em>infection are now in separate CKS topics. Together with the updated CKS topics on <em>Diarrhoea - antibiotic associated</em> and <em>Diarrhoea - prevention and advice for travellers</em>, this CKS topic replaces the former topic on <em>Gastroenteritis</em>.</p><p><strong>November 2008 </strong>— minor update to the text regarding the assessment and investigation of pregnant women with gastroenteritis. Issued in December 2008.</p><p><strong>July to September 2006 </strong>— reviewed. Validated in December 2006 and issued in January 2007.</p><p><strong>July 2007 </strong>— minor update to the text to include advice regarding the assessment and investigation of pregnant women with gastroenteritis.</p><p><strong>January 2006 </strong>— minor update. Nalidixic acid tablets discontinued and prescriptions have been removed. Issued in February 2006.</p><p><strong>June 2003 </strong>— reviewed. Validated in September 2003 and issued in October 2003.</p><p><strong>January 2000 </strong>— rewritten. Validated in March 2000 and issued in May 2000.</p><p><strong>October 1998 </strong>— written.</p><!-- end field c1375ac8-11d6-4583-aeb5-85f95078e0c0 --><!-- end item e86e4f94-3332-4e5f-bfed-48e4d4102c20 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}